QBie™ Spotlight: XORTX Therapeutics Inc. (OTCQB: XRTXF)
QBie™ Spotlight: XORTX Therapeutics Inc. (OTCQB: XRTXF)
QBie™ Spotlight joins Dr. Allen Davidoff, CEO, of XORTX Therapeutics Inc. (OTCQB: XRTXF), to discuss one of the OTCQB’s newest additions. XORTX joined the OTCQB on June 7, 2018.
What does XORTX Therapeutics do?
Dr. Allen Davidoff (CEO & President – OTCQB: XRTXF): “XORTX Therapeutics Inc., is a company focused on developing drug therapies to treat progressive kidney disease. Specifically, he company has clinical stage programs in autosomal dominant polycystic kidney disease (ADPKD) and diabetic nephropathy (DN). We are inspired by recent clinical pilot studies that show the importance of lowering and managing uric acid levels in progressive kidney disease can in turn successfully decrease the rate of progression of these serious diseases. Recent clinical study results align closely with our approach to managing the mechanism of disease action that associated with accelerating kidney disease progression. Advancing XORTX’s programs through scientifically rigorous phase II clinical trials will demonstrate the importance of this first-in-class therapeutic approach. Successful demonstration that the therapy reduces the rate of kidney disease progression promises to re-define treatment of progressive kidney disease in the future.”
What is the next big goal XRTXF is trying to accomplish/what should we keep an eye out for?
Dr. Allen Davidoff: “The company is advancing both the ADPKD and DN programs through phase II clinical trials, by completing regulatory and clinical development steps for these programs as soon as possible. In addition, XORTX hopes to announce strategic alliances with one or more international pharmaceutical companies in the near future.”
Why did you join the OTCQB/go public?
Dr. Allen Davidoff: “XORTX Therapeutics Inc. aims to develop our drug programs for progressive kidney disease by conducting proof of concept phase II clinical trials in the next 2 years. The company has granted patents and patent applications for protection of these therapeutic approaches and public markets offer the most efficient means of monetizing these unmet medical needs by increasing the access to funding.”
How can members of the microcap community help you?
Dr. Allen Davidoff: “XORTX Therapeutics currently offers an undervalued investment opportunity. Given the risk-reduced nature of our programs and opportunity for considerable value creation, XORTX will continue to explore and partner with members of the microcap community and others, that seek to share in the development of this lucrative opportunity for investors,drug developers and importantly patients suffering from these progressive diseases.”
Learn more at www.xortx.com or email Dr. Davidoff at adavidoff@xortx.com.
QBie™ Spotlight is a virtual “welcome interview” for new OTCQB companies. QBie™ Spotlight helps issuers that are new to the OTCQB connect with microcap industry professionals! Learn more about the QBie™ Spotlight HERE.
Disclaimer/Forward Looking Statements:
This Website and its contents are not to be construed, under any circumstances, as an offer to sell or a solicitation to buy or effect transactions in any securities. No investment advice is provided or should be construed to be provided herein. This Website and its owners, employees and affiliates are not, nor do any of them claim to be, registered broker-dealers or registered investment advisors. This Website may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Such forward-looking statements of or concerning the companies mentioned herein are subject to numerous uncertainties and risk factors, including uncertainties and risk factors that may not be set forth herein, which could cause actual results to differ materially from those stated herein. Accordingly, user of this Website are cautioned not to place undue reliance on such forward-looking statements. This Website undertakes no obligation to update any forward-looking statements that may be contained herein.